Related references
Note: Only part of the references are listed.RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
Mariam Gachechiladze et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Deptor: not only a mTOR inhibitor
Valeria Catena et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy
David Dingli et al.
MAYO CLINIC PROCEEDINGS (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
The Role of HMGB1 in Radioresistance of Bladder Cancer
Sanhita Shrivastava et al.
MOLECULAR CANCER THERAPEUTICS (2016)
HMGB1 interacts with XPA to facilitate the processing of DNA interstrand crosslinks in human cells
Anirban Mukherjee et al.
NUCLEIC ACIDS RESEARCH (2016)
Cytotoxic Properties of DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells
Yijiang Shi et al.
CANCER RESEARCH (2016)
HMGB1 knockdown effectively inhibits the progression of rectal cancer by suppressing HMGB1 expression and promoting apoptosis of rectal cancer cells
Zhiwei Wang et al.
MOLECULAR MEDICINE REPORTS (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
HMGB1 as biomarker and drug target
Emilie Venereau et al.
PHARMACOLOGICAL RESEARCH (2016)
Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma
Mridul Roy et al.
THERANOSTICS (2016)
Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation
Xiaorong Zhu et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Synergistic effect of HMGB1 knockdown and cordycepin in the K562 human chronic myeloid leukemia cell line
Xi Chen et al.
MOLECULAR MEDICINE REPORTS (2015)
Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis
Ruiguang Zhang et al.
TUMOR BIOLOGY (2015)
γ-H2AX as a biomarker for DNA double-strand breaks in ecotoxicology
Marko Geric et al.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY (2014)
HMGB1 in health and disease
Rui Kang et al.
MOLECULAR ASPECTS OF MEDICINE (2014)
Reovirus modulates autophagy during oncolysis of multiple myeloma
Chandini M. Thirukkumaran et al.
AUTOPHAGY (2013)
DNA repair pathways in human multiple myeloma Role in oncogenesis and potential targets for treatment
Claire Gourzones-Dmitriev et al.
CELL CYCLE (2013)
Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity
Hao-Ran Zhang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2013)
The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis
Huan Yang et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Plasmocytes tumoraux et autophagie
Laurence Lamy
M S-MEDECINE SCIENCES (2013)
Expression of HMGB1 and its Clinical Significance in T-cell Lymphoma
Xing-Jiang Mao et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1
ZhenZhen Zhan et al.
AUTOPHAGY (2012)
Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells
Liangchun Yang et al.
LEUKEMIA & LYMPHOMA (2012)
An Evolving Role for DEPTOR in Tumor Development and Progression
Zhiwei Wang et al.
NEOPLASIA (2012)
HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells
L. Liu et al.
LEUKEMIA (2011)
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma
Kevin D. Boyd et al.
LEUKEMIA & LYMPHOMA (2010)
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma
Masood A. Shammas et al.
BLOOD (2009)
Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma.
Danielle N. Yarde et al.
CANCER RESEARCH (2009)
DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
Timothy R. Peterson et al.
CELL (2009)
Masquerader: High mobility group box-1 and cancer
Jessica E. Ellerman et al.
CLINICAL CANCER RESEARCH (2007)
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells
Q Chen et al.
BLOOD (2005)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
HE Oakervee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
S Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes
C Pallier et al.
MOLECULAR BIOLOGY OF THE CELL (2003)
HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma
ML Brezniceanu et al.
FASEB JOURNAL (2003)
Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma
VJ Spanswick et al.
BLOOD (2002)
Share Paper
